找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Tamoxifen; Pioneering Medicine Philipp Y. Maximov,Russell E. McDaniel,V. Craig Jo Book 2013 Springer Basel 2013 Anti-estrogens.Apoptosis.B

[复制链接]
查看: 10552|回复: 46
发表于 2025-3-21 17:03:41 | 显示全部楼层 |阅读模式
书目名称Tamoxifen
副标题Pioneering Medicine
编辑Philipp Y. Maximov,Russell E. McDaniel,V. Craig Jo
视频video
概述The story of Tamoxifen written first-hand by the "father of tamoxifen".A personal journey through four decades of discovery that changed women’s health.Including an interview with the pioneer of the t
丛书名称Milestones in Drug Therapy
图书封面Titlebook: Tamoxifen; Pioneering Medicine  Philipp Y. Maximov,Russell E. McDaniel,V. Craig Jo Book 2013 Springer Basel 2013 Anti-estrogens.Apoptosis.B
描述.Tamoxifen is a pioneering medicine for the treatment and prevention of breast cancer. It is the first drug targeted therapy in cancer to be successful. Tamoxifen targets the tumor estrogen receptor. The therapy is known to have saved the lives of millions of women over the past 40 years..This monograph, written by V. Craig Jordan - known as the “father of tamoxifen” - and his Tamoxifen Team at the Georgetown University Washington DC, illustrates the journey of this milestone in medicine. It includes a personal interview with V. Craig Jordan about his four decades of discovery in breast cancer research and treatment. V. Craig Jordan was there for the birth of tamoxifen as he is credited for reinventing a “failed morning after contraceptive” to become the “gold standard” for the treatment of breast cancer. He contributed to every aspect of tamoxifen application in therapeutics and all aspects of tamoxifen’s pharmacology. He discovered the selective estrogen receptor modulators (SERMs) and explored the new biology of estrogen-induced apoptosis..
出版日期Book 2013
关键词Anti-estrogens; Apoptosis; Breast cancer; Estrogen receptor; SERMs
版次1
doihttps://doi.org/10.1007/978-3-0348-0664-0
isbn_softcover978-3-0348-0783-8
isbn_ebook978-3-0348-0664-0Series ISSN 2296-6056 Series E-ISSN 2296-6064
issn_series 2296-6056
copyrightSpringer Basel 2013
The information of publication is updating

书目名称Tamoxifen影响因子(影响力)




书目名称Tamoxifen影响因子(影响力)学科排名




书目名称Tamoxifen网络公开度




书目名称Tamoxifen网络公开度学科排名




书目名称Tamoxifen被引频次




书目名称Tamoxifen被引频次学科排名




书目名称Tamoxifen年度引用




书目名称Tamoxifen年度引用学科排名




书目名称Tamoxifen读者反馈




书目名称Tamoxifen读者反馈学科排名




单选投票, 共有 0 人参与投票
 

0票 0%

Perfect with Aesthetics

 

0票 0%

Better Implies Difficulty

 

0票 0%

Good and Satisfactory

 

0票 0%

Adverse Performance

 

0票 0%

Disdainful Garbage

您所在的用户组没有投票权限
发表于 2025-3-21 20:28:36 | 显示全部楼层
第100540主题贴--第2楼 (沙发)
发表于 2025-3-22 02:19:52 | 显示全部楼层
板凳
发表于 2025-3-22 04:39:26 | 显示全部楼层
第4楼
发表于 2025-3-22 09:35:39 | 显示全部楼层
5楼
发表于 2025-3-22 14:31:56 | 显示全部楼层
6楼
发表于 2025-3-22 17:36:06 | 显示全部楼层
7楼
发表于 2025-3-22 21:52:27 | 显示全部楼层
8楼
发表于 2025-3-23 01:22:32 | 显示全部楼层
9楼
发表于 2025-3-23 07:40:52 | 显示全部楼层
10楼
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-1 22:29
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表